Applying NMN to the scalp aims to raise a cellular energy helper that fuels hair-base cells, which decline with age. The strongest support is a single mouse-and-cell lab study; it may not reach the follicle through intact skin, scalp safety is uncharacterized, and product quality is unreliable. It remains experimental. (Full Review)

Protocol

Concentration

0.5% NMN

Preclinical-derived; no human concentration established

Frequency

Once–twice daily

Clean, dry scalp; consistency matters more than timing

Positioning

Unproven add-on

Not a replacement for evidence-based hair options

Time to effect

Visible change (human)

3–6 months

Estimated by analogy; unknown for topical NMN

Preclinical signal

~6 weeks

Mouse model only

Benefits

Low: Reduced DHT-driven follicle atrophy in preclinical models; local anti-inflammatory and antioxidant effect at the follicle

Speculative: Improved dermal support via collagen stimulation; carryover from oral NMN hair findings

Contraindications

Pregnancy or breastfeeding

Children

Active scalp infection or open lesions

Known sensitivity to formulation ingredients

Key Interactions

Significant kidney impairment

Co-applied topical hair drugs (minoxidil, topical finasteride)

OTC strong solvents or exfoliating acids

Oral NAD+ precursors (nicotinamide riboside, niacin)

Wnt/VEGF topicals (minoxidil, peptide serums)

Barrier-breaching procedures (microneedling, platelet-rich plasma)

Risk & Side Effects

Low: Lack of established topical safety data; local skin irritation and contact reactions

Speculative: Systemic absorption and NAD+ pathway effects; product quality and mislabeling harms

Monitoring

Marker	Target	Why
Ferritin (iron stores)	50–70 ng/mL	Low iron stores are a common, correctable cause of hair shedding
Vitamin D, 25-OH	40–60 ng/mL	Low vitamin D is associated with hair-cycle disruption; worth excluding as a confounder
TSH	1.0–2.0 mIU/L	Thyroid dysfunction is a frequent driver of diffuse hair loss to rule out
eGFR	>90 mL/min/1.73 m²	Only if systemic NMN exposure is a concern, given the theoretical kidney signal

Cadence: Matched photographs at baseline, ~3 and 6 months, then every 6 months

Qualitative Assessment

Reduced daily shedding (fewer hairs in the brush or drain)
Visible increase in density or coverage at the hairline or part
Improved hair caliber or texture (hairs feeling thicker, less wispy)
Scalp tolerability — absence of redness, itching, or flaking

Topical NMN for Hair Regrowth

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment